Although rapamycin has shown clear benefits in preclinical experiments and clinical trials for ADPKD, the precise molecular mechanism by which PC2 regulates cell growth via mTOR and how rapamycin inhibits cyst growth and epithelial‐cell proliferation have not been clarified. Here, MTOR is linked to autosomal dominant polycystic kidney disease.